Aldactone (Spironolactone) Should Be Initiated in This Patient
With a sodium of 135 mmol/L and assuming eGFR ≥30 mL/min/1.73 m² and potassium <5.0 mEq/L, spironolactone is indicated and should be started for this patient with heart failure and reduced ejection fraction. The sodium level of 135 mmol/L is at the lower limit of normal but does not contraindicate aldosterone antagonist therapy.
Key Eligibility Criteria
Your patient's sodium of 135 mmol/L meets safety thresholds. The critical parameters for spironolactone initiation are 1, 2:
- Potassium must be <5.0 mEq/L at baseline
- eGFR must be ≥30 mL/min/1.73 m² (or creatinine ≤2.5 mg/dL in men, ≤2.0 mg/dL in women)
- Sodium ≥135 mmol/L is acceptable - hyponatremia is not listed as a contraindication in major guidelines
Evidence-Based Benefits
Spironolactone reduces mortality by 30% and heart failure hospitalizations by 30% in patients with HFrEF 3. The landmark RALES trial demonstrated these benefits in NYHA class III-IV patients with LVEF ≤35% 3. More recent evidence from EMPHASIS-HF extended benefits to milder symptoms (NYHA class II) 2.
Practical Initiation Protocol
Start with 12.5-25 mg once daily 1, 2. For patients with borderline renal function (eGFR 30-49 mL/min/1.73 m²), consider starting at 12.5 mg daily or even every other day 1.
Monitoring Schedule (Critical to Prevent Hyperkalemia)
The monitoring protocol is non-negotiable 1, 4, 2:
- Check potassium and creatinine within 2-3 days after initiation
- Recheck at 1 week
- Monthly monitoring for first 3 months
- Every 3 months thereafter
Medication Adjustments at Initiation
- Discontinue potassium supplements when starting spironolactone 1, 4
- Counsel patient to avoid high-potassium foods and salt substitutes (which often contain potassium) 5
- Avoid NSAIDs - they increase hyperkalemia risk and cause diuretic resistance 5, 4
Managing Hyperkalemia Risk
If potassium rises to 5.5-5.9 mEq/L: Reduce spironolactone dose to 12.5 mg every other day or hold temporarily 1
If potassium ≥6.0 mEq/L: Discontinue spironolactone until potassium <5.0 mEq/L, then consider restarting at lower dose 1
Common Pitfalls to Avoid
The real-world experience post-RALES publication showed a concerning increase in hyperkalemia-related hospitalizations when spironolactone was prescribed outside trial criteria 4, 6. Approximately 31% of prescriptions were given to patients not meeting enrollment criteria, including those with elevated creatinine or potassium 6. This underscores the importance of strict adherence to eligibility criteria and monitoring protocols.
Special Considerations
Triple therapy caution: The combination of ACE inhibitor + ARB + spironolactone significantly increases hyperkalemia risk and is NOT recommended 5, 4. Use spironolactone with either an ACE inhibitor OR ARB, not both.
Dehydration episodes: Instruct patients to temporarily hold spironolactone during diarrhea, vomiting, or other dehydrating illnesses 4, 5. Loop diuretic interruption should also trigger spironolactone hold.
Gynecomastia: Occurs in 6.9% at doses <50 mg/day and 52% at doses >150 mg/day 7. If this becomes problematic, consider switching to eplerenone (more selective, fewer anti-androgen effects) 1, 7.
Sodium Level Context
While your patient's sodium of 135 mmol/L is at the lower end of normal, hyponatremia is not a contraindication to spironolactone in the major HF guidelines 1, 2, 3. The primary concerns are hyperkalemia and renal dysfunction. Monitor sodium levels as part of routine electrolyte surveillance, but this should not prevent initiation if other criteria are met.
The mortality and morbidity benefits of spironolactone in eligible HFrEF patients are substantial and evidence-based 3. With appropriate patient selection, careful monitoring, and patient education about warning signs, spironolactone therapy is both safe and highly beneficial.